{"denoms":[{"counts":[{"groupId":"BG000","value":"129"}],"units":"Participants"}],"groups":[{"description":"Belinostat 1000 mg/m\\^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.","id":"BG000","title":"Belinostat"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"29","upperLimit":"81","value":"63"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"69"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Full Analysis Set included all participants who were received at least 1 dose of belinostat."}